The methyl-CpG binding domain (MBD) family of proteins was de®ned based on sequence similarity in their DNA binding domains. In light of their high degree of conservation, it is of inherent interest to determine the genomic distribution of these proteins, and their associated co-repressor complexes. One potential determinant of speci®city resides in differences in the intrinsic DNA binding properties of the various MBD proteins. In this report, we use a capillary electrophoretic mobility shift assay (CEMSA) with laser-induced¯uores-cence (LIF) and neutral capillaries to calculate MBD±DNA binding af®nities. MBD proteins were assayed on pairs of methylated and unmethylated duplex oligos corresponding to the promoter regions of the BRCA1, MLH1, GSTP1 and p16 INK4a genes, and binding af®nities for each case were calculated by Scatchard analyses. With the exception of mammalian MBD3 and Xenopus MBD3 LF, all the MBD proteins showed higher af®nity for methylated DNA (in the nanomolar range) than for unmethylated DNA (in the micromolar range). Signi®cant differences between MBD proteins in the af®nity for methylated DNA were observed, ranging within two orders of magnitude. By mutational analysis of MBD3 and using CEMSA, we demonstrate the critical role of speci®c residues within the MBD in conferring selectivity for methylated DNA. Interestingly, the binding af®nity of speci®c MBD proteins for methylated DNA fragments from naturally occurring sequences are affected by local methyl-CpG spacing.
INTRODUCTION
Methylation at position 5 in cytosines is the most common modi®cation of vertebrate genomes. In mammals, this modi®cation occurs almost exclusively in CpG dinucleotides. In fact, 70% of all CpG dinucleotides are methylated in mammals, with the exception of CpG islands, which are CG-rich regions mostly coincident with the promoter of protein-coding genes. In some circumstances, many CpG islands become hypermethylated, resulting in gene silencing. For instance, promoter hypermethylation of tumor suppressor and DNA repair genes has been linked to cancer, and the study of methylation changes in cancer constitutes an important branch of study in cancer research (1) . In this context, methylCpG binding proteins appear to be central players in the process of DNA methylation-dependent gene silencing (2) . This family of proteins takes its de®nition from the methylCpG binding domain (MBD), the minimum portion with speci®c af®nity for a single symmetrically methylated CpG pair. The MBD was characterized by deletion studies of MeCP2 (3) . After the recognition of the MBD, four additional genes were found to contain this domain, namely MBD1, MBD2, MBD3 and MBD4 (4) .
The biochemistry of MBD proteins has been studied at different levels. In general, all MBD proteins, except MBD4, have been reported to be associated with histone deacetylase subunits as parts of large multisubunit complexes. For instance, MBD3, the best characterized member of the MBD family from a biochemical point of view, has been determined as being a component of a complex called Mi-2/NURD that contains a chromatin-remodeling ATPase, a histone deacetylase and other subunits (5) . In mammals, MBD2 recruits the MeCP1 histone deacetylase complex to DNA. The MeCP1 complex contains 10 major polypeptides, including MBD2 and all of the known NuRD components (6) .
Some of the currently available data suggest that different MBD protein-containing complexes are targeted speci®cally to different methylated promoters (2) , although it is possible that MBDs play no role in recognizing particular sequences. A few studies support the notion of selectivity in the association of MBD with particular promoters (7±9). However, the fact that MBD2 knockout mice are viable has been interpreted as if MBD proteins are at least partially redundant (10) .
One of the still unresolved matters is the quantitative contribution of the MBD proteins to the association of their complexes with speci®c loci. While the MBD domain is highly conserved, seemingly minor sequence differences could produce alterations in af®nity for methylated DNA. This could range from a high selectivity for methylated CpG sites to a complete lack of binding. Supporting this notion, DNase I footprinting of the MeCP2-MBD on DNA showed that the methyl-CpG site was~50% protected against DNase I at an MBD concentration of 1.25 Q 10 ±9 M, indicating a dissociation constant close to this value (3) . On the other hand, electrophoretic mobility shift asssy (EMSA) and southwestern analysis of mammalian MBD3 indicate that this protein cannot speci®cally recognize methylated DNA (4) , in contrast to its amphibian homolog, which has been shown to bind methylated DNA selectively (5) . Quantitative characterization of the binding to a single methyl-CpG pair of different MBD proteins remains a key issue in the evaluation of their contribution to the targeting to a promoter. Additional matters requiring further characterization are the in¯uences of methyl-CpG density and local sequence context on binding. For instance, early results suggested that the MeCP1 complex, which was later demonstrated to contain MBD2 (11) , requires at least 12 consecutive CpGs to bind methylated DNA (12) . Although MBD2 has been demonstrated to recognize a single methylated CpG pair, it is possible that MBD2 prefers more densely methylated DNA. In other words, the density or distribution of methyl-CpGs may in¯uence MBD2 binding. EMSAs and southwestern analysis are suitable and convenient techniques for qualitatively evaluating the association of MBDs with DNA. However, additional techniques need to be used to obtain reliable quantitative data on af®nities between MBD proteins and methylated DNA. Capillary electrophoresis (CE) has become a useful technique for measuring binding constants. Compared with classical EMSA, in CE caging effects are avoided and the conditions are closer to the equilibrium; therefore, the fraction of protein±DNA complexes separated during the electrophoretic procedure is smaller than in EMSA (13) .
To quantify protein±DNA binding af®nities, we have used a modi®cation of the high-performance capillary electrophoresis-based method called CEMSA (capillary electrophoretic mobility shift assay) (14) . This modi®cation, termed R-CEMSA (reverse capillary electrophoresis mobility shift assay), is a quantitative, simple and rapid method for calculating binding af®nities that employs neutral-coating capillaries in order to avoid protein adsorption onto the capillary walls. We make use of this quantitative method to calculate the half-saturation concentration for DNA binding proteins to evaluate the intrinsic contribution of the binding properties of MBD proteins to their selective recruitment to promoters. Two issues have been addressed, namely whether different MBD proteins have signi®cantly different binding af®nities for a model methylated sequence, and whether an MBD protein is signi®cantly affected by local sequence context and methyl-CpG density. Our results indicate that CpG distribution along the sequence may in¯uence the interaction of each MBD protein with DNA.
MATERIALS AND METHODS

Reagents
DNAs, purchased as single-stranded oligonucleotides (Operon-Qiagen), were as follows: forward GAC, GAT CCG ACG ACG ACG ACG ACG ACG ACG ACG ACG ACG ACG ATC; reverse GAC, GAT CGT CGT CGT CGT CGT CGT CGT CGT CGT CGT CGT CGG ATC; forward GAM1 (monomethylated GAC), GAT CCG ACG ACG ACG ACG AXG ACG ACG ACG ACG ACG ACG ATC; reverse GAM1 (monomethylated GAC), GAT CGT CGT CGT CGT CGT CGT XGT CGT CGT CGT CGT CGG ATC, where X stands for 5-methyl-C; forward GSTP1, CCC TCC AGA AGA GCG GCC GGC GCC GTG ACT CAG CAC TGG GGC GGA GCG GG; reverse GSTP1, CCC GCT CCG CCC CAG TGC TGA GTC ACG GCG CCG GCC GCT CTT CTG GAG GG; forward MLH1, GAA CGT GAG CAC GAG GCA CTG AGG TGA TTG GCT GAA GGC ACT TCC GTT GA; reverse MLH1, TCA ACG GAA GTG CCT TCA GCC AAT CAC CTC AGT GCC TCG TGC TCA CGT TG; forward p16 INK4a , GCG CTC GGC GGC TGC GGA GAG GGG GAG AGC AGG CAG CGG GCG GCG GGG AG; reverse p16 INK4a , CTC CCC GCC GCC CGC TGC CTG CTC TCC CCC TCT CCG CAG CCG CCG AGC GC; forward BRCA1, AAA ACT GCG ACT GCG CGG CGT GAG CTC GCT GAG ACT TCC TGG ACG GGG GA; and reverse BRCA1, TCC CCC GTC CAG GAA GTC TCA GCG AGC TCA CGC CGC GCA GTC GCA GTT TT. Oligonucleotides corresponding to natural promoter CpG islands were obtained as fully methylated and unmethylated versions. In order to perform a systematic analysis of the in¯uence of the methyl-CpG density and spacing on binding of MBD proteins, six different versions of the BRCA1 oligos were obtained: a non-methylated version, a monomethylated oligo with the methyl-CpG at the third CpG (BRCA1-M), and two different dimethylated oligos with methyl-CpG at the third and fourth CpGs (BRCA1-D1) or the third and sixth positions (BRCA1-D2). Finally, two different trimethylated oligos were obtained with the methyl-CpGs at positions 2, 3 and 4 (BRCA1-T1) or 1, 3 and 6 (BRCA1-T2) (Fig. 4E) .
Forward oligonucleotides were labeled at their 5¢ ends with 6-FAM. Complementary oligonucleotides were mixed at equimolar concentrations, and annealed by bringing the solution to 95°C and allowing it cool down slowly to room temperature.
Mouse MeCP2 was subcloned in pET23b from the IMAGE clone 4948925 using NdeI and XhoI.
Construction of MBD3 mutations
The coding sequence of mouse MBD3 was ampli®ed from pET MBD3 (4) using the following primers: sense, CAT ATG GAG CGG AAG AGG TGG GAG; antisense, CTC GAG CAC TCG CTC TGG CTC CGG CTC. The ampli®cation product was T/A cloned (Topo T/A, Invitrogen) and sequenced on both strands. The coding sequence was then subcloned into pET21a using NdeI and XhoI. Mutations were introduced into the resulting MBD3 pET21a clone by oligonucleotide-directed mutagenesis (QuickChange, Stratagene). The following mutagenic oligonucleotides were used: F34Y sense, GCC GGC CAC AGG GAT GTC TAT TAC TAT AGC CCC AGC; F34Y antisense, GCT GGG GCT ATA GTA ATA GAC ATC CCT GTG GCC GGC; H30K sense, GGG CTG TCG GCC GGC AAA AGG GAT GTC TTT TAC; H30K antisense, GTA AAA GAC ATC CCT TTT GCC GGC CGA CAG CCC; H30K, F34Y sense; GGG CTG TCG GCC GGC AAA AGG GAT GTC TAT TAC TAT AGC CCC AGC GGG; and H30K, F34Y antisense, CCC GCT GGG GCT ATA GTA ATA GAC ATC CCT TTT GCC GGC CGA CAG CCC. All mutagenized clones were veri®ed by DNA sequencing.
Puri®cation of recombinant protein
Recombinant mouse MeCP2, MBD2b and MBD3, and Xenopus MeCP2, MBD3 and MBD3 LF were expressed in Escherichia coli BL21 (DE3). A 500 ml aliquot of LB was inoculated with 5 ml of an overnight culture and incubated at 37°C to an A 600 of 0.7. Induction was performed by the addition of isopropyl-b-D-thiogalactosidase to 0.5 mM and incubation at 37°C for a further 4 h. Cells were harvested and resuspended in 10 ml of extraction/wash buffer (50 mM sodium phosphate pH 7.0, 300 mM NaCl, 0.1% NP-40, 1 mM 2-mercaptoethanol). Puri®cation of the soluble His-tagged protein was performed with TALON resin (Clontech), according to the manufacturer's protocol. Protein was dialyzed against 20 mM Tris±HCl pH 8.0, 300 mM NaCl. Quanti®cation was performed using the BioRad protein assay and routinely checked by 12% SDS±PAGE.
Gel mobility shift and southwestern assays
Binding reactions for mobility shift assays were performed in binding buffer as described by Wade et al. (5). 6-FAM-labeled DNAs were ®rst radiolabeled. Increasing amounts of MBD proteins were added to 6-FAM-labeled DNAs in binding buffer [10 mM Tris-HCl pH 8.0, 3 mM MgCl 2 , 50 mM NaCl, 0.1 mM EDTA, 0.1% NP-40, 2 mM dithiothreitol (DTT), 5% glycerol and 0.4 mg/ml bovine serum albumin (BSA)] and incubated overnight at 4°C. Gel mobility shifts were performed in 10% polyacrylamide gels run in 0.5Q TBE buffer (45 mM Tris pH 8.0, 45 mM boric acid, 1 mM EDTA) using GAC or GAM1 double-stranded oligonucleotide probes. One picomole of 6-FAM-labeled probe was mixed with puri®ed recombinant protein, as indicated in the ®gure legends, in 10 mM Tris±HCl pH 8.0, 3 mM MgCl 2 , 50 mM NaCl, 0.1 mM EDTA, 0.1% NP-40, 2 mM DTT, 5% glycerol and 0.4 mg/ml BSA. The samples were incubated for 30 min at 37°C. A total of 30 pmol of competitor DNA (GAC or GAM1) was used per binding reaction. Gels were scanned on a PhosphorImager (Molecular Dynamics). The procedure used for southwestern assay was as described (15), except for the use of 6-FAMlabeled oligos.
Capillary electrophoresis mobility shift assay
A neutral-coating capillary (Beckman Coulter S.A.) (32.5 cm Q 50 mm, effective length 20 cm) was used in a P/ACE MDQ capillary electrophoresis system (Beckman Coulter S.A.) connected to a Karat Software â data-processing station. The running buffer (40 mM Tris-borate, 0.95 mM EDTA, pH 8.0) was chosen to provide a low current when working at high voltage (30 kV, 923 V/cm) in order to maintain the stability of protein±DNA complexes during separation. Laser-induced uorescence (LIF) was detected by excitation at 488 nm (3 mW argon ion laser provided by Beckman Coulter S.A.), and emissions were collected through a 520 nm emission ®lter (Beckman Coulter S.A.). Samples were injected under pressure (0.2 p.s.i.) for 2 s and the run temperature was maintained at 20°C. Before each run, the capillary was conditioned by washing with running buffer for 2 min. Buffers and running solutions were ®ltered through 0.2 mm pore-size ®lters. Three replicates of each concentration were prepared, and each was run twice.
Binding reactions were performed in binding buffer as described by Wade et al. (5) . Increasing amounts of all MBDs were added to 6-FAM-labeled DNAs in binding buffer (10 mM Tris±HCl pH 8.0, 3 mM MgCl 2 , 50 mM NaCl, 0.1 mM EDTA, 0.1% NP-40, 2 mM DTT, 5% glycerol and 0.4 mg/ml BSA) and incubated overnight at 4°C.
Binding af®nities were quanti®ed by Scatchard analyses using GraFit 3.1 software (Fig. 2) . In brief, the saturation of the oligo (R = ) was then calculated, seeking the best ®t of the data to different binding models/curves.
Molecular modeling
On the basis of the close homology between different MBD domains, models of murine MBD2-and MBD3-and Xenopus MBD3-binding domains were developed using the NMR structure of human MBD1 as reference, with the program Whatif (16) , following the program manual.
MBD domain boundaries were identi®ed after sequence alignment using ClustalX (17) , and the BLDPIR routine of Whatif was used to build the models.
RESULTS AND DISCUSSION
Prior to initiating quantitative DNA binding experiments using CEMSA, we performed classical DNA binding experiments (mobility shift assays and southwestern blot analysis) to determine whether introduction of a¯uorescent probe altered MBD±DNA interactions (Fig. 1) . Southwestern blots were performed with both unmethylated and methylated probes, (GAC and GAM1; described in Materials and Methods). In agreement with previous results (4,5), Xenopus MeCP2, Xenopus MBD3 and murine MBD2b selectively bind 6-FAM-GAM1 (Fig. 1A, central panel) . In contrast, murine MBD3 and Xenopus MBD3 LF, a splice variant of MBD3, with its MBD disrupted by an insertion (Fig. 1C) , showed no af®nity for this probe (Fig. 1A, central panel) . No binding to the unmethylated probe, 6-FAM-GAC, was observed in any case (Fig. 1A, right panel) . Mobility shift assays produced results similar to the analysis by southwestern assays. As an example, MeCP2 binding to 6-FAM-GAM1 is shown (Fig. 1B) . repeats, where the central CpG is methylated. The methylated CpG pair is located at the central repeat in order to ensure that the MBD protein establishes all the contacts required for its correct positioning along the DNA. An unmethylated version of this oligonucleotide was also used to evaluate non-speci®c contributions of binding to DNA. Several proteins were analyzed, namely Xenopus MeCP2, MBD3 and MBD3 LF, and murine MeCP2, MBD2b and MBD3. Addition of MBD proteins to the 6-FAM-labeled duplex oligo GAM1 produced a discrete, sharp peak on capillary electrophoresis. Excellent resolution of free DNA and DNA±MBD complexes was obtained ( Fig. 2A) , with no gel matrix required, thus avoiding putative caging effects on the calculated binding af®nities (18) . Under these conditions, the migration time of the free oligo was~4 min while for the complex it was~5 min, regardless of the MBD protein type. The appearance and subsequent increase of the protein±DNA complex was concomitant with the decrease in the area of the peak corresponding to the free probe. BSA, used as a negative control, did not produce any retardation peak (not shown). A discrete complex also appeared when the unmethylated oligo GAC1 was used. However, the amount of MBD protein required to obtain a retardation peak was signi®cantly greater.
Titrations were repeated three times for each of the MBD proteins. The results were plotted as saturation fraction against MBD protein concentration (Fig. 2B and C) . The data follow classical saturation plots, and the protein concentrations required for 50% saturation of binding (R 1/2 ) were calculated using GraFit software. We observed striking differences among MBD proteins, particularly in the case of mammalian MBD2b, which showed the highest af®nity for methylated DNA (Table 1) , 2.7 T 0.8 nM. In contrast, Xenopus MBD3 showed a signi®cantly lower af®nity for GAM1, 186.5 T 42.5 nM. Non-speci®c binding to the unmethylated versions of these oligonucleotides was also observed. In fact, addition of MBDs to the oligonucleotide resulted in the appearance of a discrete complex, similar to that observed with methylated DNA. However, the R 1/2 values of the unmethylated oligos were all within the same micromolar range (Fig. 2C) , indicating that the relative contribution of non-speci®c binding was signi®cantly lower than that of speci®c interaction. Xenopus MBD3 LF failed to produce a retardation peak for either methylated or unmethylated DNA.
Interestingly, the comparison of binding properties of Xenopus MeCP2 versus murine MeCP2 indicates that the former has a higher af®nity for the methylated probe than the latter, indicating that minor sequence differences can result in substantial changes in DNA binding properties. It is unlikely that differences in af®nity could be attributed to the four changes within the MBD sequence, namely amino acid residues at positions 7, 31, 39 and 54 (Fig. 1C) , since structural data (19) have not assigned an essential role for any of these residues. Instead, it is possible that differences in the binding properties of these two proteins could be due to their differences in the sequence outside the MBD.
We also analyzed the binding properties of mammalian MBD3. In agreement with previous observations (4), mMBD3 showed no ability to recognize methylated DNA selectively (see Fig. 3B and C) . For both the unmethylated and methylated oligo, the retardation peak appeared only at micromolar concentrations and the R 1/2 values were very similar, suggesting that MBD3 only interacts non-speci®cally with DNA.
Amino acid substitutions alter the af®nity of mammalian MBD3 for methylated DNA Our results concerning the lack of selectivity to bind methylated DNA by murine MBD3 can be interpreted in terms of current structural data. On the basis of the close homology between different MBD domains, models of murine MBD2-and MBD3-and Xenopus MBD3 binding domains were produced with the program Whatif (16), taking the NMR structure of human MBD1 as reference. These structural models shed light on the binding mechanism of different proteins that contain MBDs. Furthermore, the models based on the NMR structure of MBD1 support the proposed molecular mechanism. In the case of mammalian MBD3, the absence of binding has been attributed to the presence of phenylalanine instead of a highly conserved tyrosine in position 34 (20) . The disruption of the hydrogen bond between the hydroxyl group of Tyr34 and the amino group of C6 can be observed in the model of murine MBD3 (Fig. 3A) . This change should not disturb important interactions such as that of the guanidinium group of Arg44 with the p-electron cloud of the aromatic ring of the amino acid in position 34, which ensures the correct positioning of the Arg44 side chain (Fig. 3A) . However, some additional changes, due to the presence of histidine and arginine in positions 30 and 31 in the murine MBD3 sequence instead of the invariant lysine/ arginine and serine conserved in other MBDs, might contribute to the loss of selectivity for methylated DNA.
To test our hypothesis, we prepared point mutations of murine MBD3 (described in Materials and Methods). In particular, we focused on Phe34 and His30, since these residues are the only two conserved in all MBD proteins except for mMBD3, and prepared single mutants for each of these residues and a double mutant form of MBD3. Recombinant proteins were produced and puri®ed as described above. Binding properties of the mutants were tested by CEMSA with GAM1 and GAC oligos and compared with wild-type MBD3. In all three mutant forms, an increase in af®nity for methylated DNA was observed. Figure 3B shows the appearance of the retardation peak at the same concentration of each MBD3 form. Titrations for each MBD3 form were performed as described above. The af®nity for unmethylated probe was similar in all three mutants and comparable with wild-type mammalian MBD3 (Fig. 3D) , indicating that the point mutations did not alter non-speci®c binding. In contrast, the R 1/2 values for methylated DNA were decreased substantially (Fig. 3C) . Both the F34Y and H30K mutants exhibited increased selectivity for the methylated substrate, with the F34Y mutant demonstrating marginally improved speci®city. The double mutation (F34Y, H30K) resulted in a small improvement in differential interaction compared with the F34Y mutation alone (R 1/2 value of 71.3 versus 80.71 nM; see Fig. 3C ). These results suggest that the tyrosine hydroxyl interaction with cytosine is crucial for selective interaction with methylated DNA and can only be partially compensated for by the histidine to lysine change at position 30. Our results are in agreement with data recently published by Saito and Ishikawa (21) , which also found that both residues H30 and F34 are responsible for the inability of mammalian MBD3 to bind mCpG. However, in contrast to their results, which indicate that H30K itself has no stimulatory effect on binding of MBD3 to methylated DNA, we observed that this single mutation is able to enhance the speci®c binding af®nity for methylated DNA~4.5-fold. It is conceivable that this difference can be due to the different separation technique employed in each case. Surprisingly, the point mutant forms of mMBD3 had better af®nity for methylated DNA than Xenopus MBD3. A possible explanation for this is that xMBD3 has a deletion of the proline residue at position 12 (see Fig. 1C ). The NMR structures of the MBDs of MeCP2 and MBD1 (19, 22) show that this residue provides a sharp turn between b-strands 1 and 2, and thus contributes to the organization of the MBD fold. Mutations at the equivalent position (P101) in human MeCP2 have been correlated with Rett syndrome (23) .
MBD proteins are in¯uenced by both sequence features and methyl-CpG density
An additional experimental question of relevance for MBD±DNA interactions is whether the density of methylCpGs or local sequence context affect binding af®nity. We designed oligos corresponding to four different CpG islands that become methylated in cancer (Fig. 4D) . The selected sequences correspond to 50 bp portions of CpG islands of the BRCA1, GSTP1, p16 INK4a and MLH1 genes. These oligos differ both in methyl-CpG density and in DNA sequence.
In CEMSA, we observed the appearance of retardation peaks concomitant with the decrease of the free DNA peak (Fig. 4A) . Considering the resolution of this technique, the appearance of a single peak can be interpreted as resulting from the formation of a complex comprising one molecule each of DNA and of protein. The incorporation of additional molecules of MBD proteins should result in the appearance of additional peaks, as is apparent on the addition of excess amounts of xMeCP2 to the methylated BRCA1 DNA (Fig. 4A) . We therefore interpreted our results as representing the formation of a single complex, even when more than one CpG pair was present for each oligo. A subset of the primary data for these experiments is shown in Figure 4 ; Table 1 shows the R 1/2 values for each MBD on each fragment. In general, the R 1/2 values for methylated DNA followed the pattern observed on the model GAM1 substrate. MBD2b had the strongest af®nity for the substrate, reaching half-saturation at single digit nanomolar concentrations (Table 1) . xMeCP2, mMeCP2 and xMBD3 reach halfsaturation on methylated substrates at somewhat higher concentrations, ranging from 20 to 120 nM (Fig. 4 and Table 1 ). The ability of a given MBD to discriminate between unmethylated and methylated versions of the same DNA fragment can be determined by calculating the ratio of the R 1/2 values for unmethylated DNA divided by the same value for methylated DNA. MBD2b displays the greatest capacity to differentiate, with 30-to 130-fold differences between halfsaturation values for unmethylated versus methylated DNA. In contrast, xMeCP2 and xMBD3 displayed only 5-to 20-fold differences. Curiously enough, mMeCP2 only showed around 3-fold differences between half-saturation values for unmethylated versus methylated oligos. The molecular basis for this increased ability to differentiate between MBD2b and the other three proteins currently is unclear. It has to be mentioned that MBD2b is a minor fraction of the total MBD2 protein.
The major form of MBD2, MBD2a, contains an N-terminal extension of 152 amino acids proximal to the MBD which may signi®cantly affect the binding af®nity of the protein.
Two variables determine methylation density, the absolute number of methyl-CpG pairs and how tightly they are clustered on a given substrate. The DNA fragments used in this study have three (MLH1), six (BRCA1 and GSTP1) or seven (p16 INK4a ) methyl-CpG dinucleotides. MBD2b has roughly equivalent af®nity for the p16 INK4a and GSTP1 fragments, with the lowest af®nity for MLH1, the fragment with the fewest methyl-CpG pairs (Table 1) . xMeCP2, on the other hand, had the highest af®nity for the BRCA1 fragment, followed by GSTP1, p16 INK4a and MLH1. Finally, xMBD3 preferred GSTP1, followed by BRCA1, p16 INK4a and MLH1. It is thus apparent that the absolute number of CpGs affects binding af®nity, as expected. MLH1 has roughly half the number of methyl-CpGs and is the poorest substrate for all three proteins.
It is informative to compare the R 1/2 values of these MBD proteins for the two fragments with the same number of methyl-CpGs, GSTP1 and BRCA1. MBD2b, mMeCP2 and xMBD3 bind more avidly to GSTP1, while xMeCP2 binds better to BRCA1 (Table 1) . Differences in af®nity for these two fragments with the same number of CpGs could be due to two different effects, local sequence or CpG distribution.
In order to assess the relative effects of methyl-CpG spacing and density in the context of a natural sequence in a more systematic manner, we prepared ®ve different oligos with the BRCA1 sequence in which one, two or three of its CpG dinucleotides were methylated with different spacing (Fig. 4E) . Figure 4F summarizes the results obtained with the ®ve differentially methylated BRCA1 oligos and the two versions of MeCP2. We observed that xMeCP2 and mMeCP2 have a lower af®nity for any of the partially methylated BRCA1 oligos than the af®nity observed for the fully methylated BRCA1 oligo (Table 1) . This result supports the notion that the absolute number of CpGs affects binding. Furthermore, although only small differences were observed among the different partially methylated BRCA1 oligos, ranging within 2-fold, the behavior of both Xenopus and mouse MeCP2 was similar, suggesting that these differences were signi®cant. The poorest af®nity observed for both xMeCP2 and mMeCP2 was obtained with the dimethylated oligo with the shortest spacing (BRCA1-D1). It is possible that the existence of an additional methyl-CpG within the 12 bp protected by the MBD (24) acts as a discouraging feature for binding.
Finally, our results do not allow local sequence effects on af®nity to be ruled out. However, the binding af®nities of MeCP2 for monomethylated oligos (GAM1 and BRCA1-M) and trimethylated oligos (MLH1 and BRCA1-T2) were virtually identical regardless of the sequence, suggesting that at least in the above examples no sequence effects occur.
The major conclusions of this work are consistent with the likelihood that, at least in some instances, the binding properties of a given MBD protein can in¯uence its targeting to a speci®c locus. We have observed that small sequence differences in the MBD domain are manifested in rather striking changes in DNA recognition properties. The ®nding that the F34Y mutant version of mMBD3 selectively recognizes methylated DNA signi®cantly better than xMBD3 strongly supports this notion. We also observed that, on naturally occurring sequences, increases in the total number of methyl-CpG pairs resulted in increased binding af®nity. Of course, increasing the total number of methylCpGs per fragment serves to increase the number of available binding sites. Most interesting of all, there appears to be an additional determinant of binding af®nity related to either the spacing of methyl CpGs or to local sequence context. Whatever the molecular determinants of the differences observed in this work, they suggest that MBD proteins are likely to be differentially localized within the genome, at least in part, as a direct re¯ection of their inherent binding preferences.
Obviously, additional factors associated with MBD complexes should be involved in their speci®c recruitment to particular promoters. Therefore, based on our data, it seems that all potential substrates will bind MBD2 in preference to other MBD proteins. However, this is not the situation in vivo. Additional factors (the N-terminal extension in MBD2a, other proteins complexed to the MBD proteins; chromatin context) may well have effects in vivo. The current results concerning the targeting of MBD to hypermethylated promoters support this model. In fact, the speci®c association of the MBD complex with diverse loci has been demonstrated in a few cases (7±9). Although determinants of speci®c targeting remain unknown, sequence-speci®c transcription factors are likely to be involved in the selective recruitment of MBDcontaining complexes by interaction with any of their subunits. For instance, Drosophila Mi-2, a component of ā y MBD-containing complex, interacts with the Hunchback transcriptional repressor, which binds directly to regulatory sequences of HOX genes (25) . Also, the zinc ®nger protein Ikaros interacts with Mi-2 in erythroid cells (26) . The observation that dMBD-like, the Drosophila MBD2/3 homolog, which is unable to bind methylated DNA, is associated with discrete loci suggests that this protein is targeted within the genome by interactions with sequence-speci®c DNA binding proteins (27) .
The overall picture can accommodate not only speci®c targeting but also partial redundancy. Fine-scale regulation of the expression levels of MBD proteins may contribute to the selection of the MBD complex involved in the repression at speci®c sites (28) . Differences in the af®nity of different MBD proteins for methylated DNA, as demonstrated in the current study, must surely play a role in the selective recruitment of MBDs to promoters.
